Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification

ConclusionBI-907828 showed significant anti-tumor activity in DDLPS PDX harboringMDM2 amplifications, providing a strong rationale for early clinical testing of BI-907828 in a DDLPS patient population.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research